Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Nov 11 2020

Full Issue

Russia Claims Sputnik Vaccine Shows More Than 90% Efficacy

The country's announcement follows Pfizer's reporting of a similar breakthrough. Late-stage trials have not yet finished.

Reuters: Russia Says Its Sputnik V COVID-19 Vaccine Is 92% Effective 

Russia’s Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, the country’s sovereign wealth fund said on Wednesday, as Moscow rushes to keep pace with Western drugmakers in the race for a shot. The initial results are only the second to be published from a late-stage human trial in the global effort to produce vaccines that could halt a pandemic that has killed more than 1.2 million people and ravaged the world economy. (Ivanova, 11/11)

Bloomberg: Russia Says Tests Prove Its Covid-19 Vaccine Over 90% Effective

The developer of Russia’s flagship vaccine against Covid-19 said it shows a 92% efficacy rate in preventing infections, as the country pushes for a top slot in the fight against the coronavirus after a rival product by Pfizer Inc. reported a similar breakthrough. The preliminary Phase 3 findings are based on results from 20,000 volunteers who were given the first dose, including more than 16,000 who also received a second injection, its developers Gamaleya Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund said in an announcement on Twitter Wednesday. (Meyer and Kravchenko, 11/11)

The Wall Street Journal: Russian Coronavirus Vaccine Rollout Plans Hit Production Speed Bumps 

Russia’s plan to roll out its coronavirus vaccine to the wider population is progressing at a slower pace than expected as policy makers encounter challenges in ramping up production. Russia in August became the first country to approve a Covid-19 vaccine, called Sputnik V, despite skepticism in the West over the speed with which it was developed and the fact that trials were still ongoing. Moscow has since registered a second vaccine and authorities say a third could be approved next month. (Kantchev, 11/10)

Reuters: Turkey Interested In Producing Russia's Sputnik V Vaccine: Russian Health Ministry

Turkey is interested in producing Russia’s first coronavirus vaccine, Sputnik V, at domestic facilities, Russia’s health ministry said on Wednesday after a phone call between the countries’ health ministers. Russia is already testing two vaccines against the virus and is on the cusp of registering a third. It is rolling out its Sputnik V vaccine for domestic use despite the fact that late-stage trials have not yet finished. (11/11)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF